| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a74cd20d8ab85bfb03c6b7e3ef934a48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0ce3e920d504c2b648553cbe61be9bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3c2e77f8dfda692ca527454d23ecc03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2021-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0c6072165f397d5f87443801ab23ca4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9a7bdd6e9250ca16c9c64fdd1e0e5eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98d7dbd8e703e68acf18e9ec014a821b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0eb5d7d700c8fc9e4431a6f6fe62eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_478f918428bdc95378e157e6218bc95a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be6ad75f730755832f7f5b33dc75bfdf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3132ae704f9e5b7536da3bd0b0e9925
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a550f943aca0a1ed02f35115917d514
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98e4f5502e97300565656b40b4fae567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6c0927d10a931fef62f23bea41fb9f9 |
| publicationDate |
2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022140181-A1 |
| titleOfInvention |
Methods of administering intravenous baclofen |
| abstract |
Methods tor the intravenous (IV) administration of a therapeutically effective amount of baclofen at a dosing regimen winch mimics the oral pharmacokinetic profile of baclofen are disclosed. The disclosed methods meet bioequivalence criteria for both systemic exposure (AUC) and maximum plasma concentration (Cmax) compared to oral administration. |
| priorityDate |
2020-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |